5 FDA decisions to watch in the second quarter

The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Click here to view Pennsylvania NY/NJ Biotech Networks Trending News